Moomoo AI 已提取核心信息
On December 31, 2023, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G with the United States Securities and Exchange Commission, disclosing a 9.99% ownership stake in 180 Life Sciences Corp. The filing indicates that Armistice Capital, LLC and Steven Boyd collectively hold 1,112,480 shares of common stock in the company. The shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC acts as the investment manager, granting it voting and investment power over the securities. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of 180 Life Sciences Corp. The percentage ownership is based on 11,135,940 shares outstanding as of December 26, 2023, as reported in the company's Schedule 14A filed with the SEC. The filing was completed on February 14, 2024.
On December 31, 2023, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G with the United States Securities and Exchange Commission, disclosing a 9.99% ownership stake in 180 Life Sciences Corp. The filing indicates that Armistice Capital, LLC and Steven Boyd collectively hold 1,112,480 shares of common stock in the company. The shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC acts as the investment manager, granting it voting and investment power over the securities. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of 180 Life Sciences Corp. The percentage ownership is based on 11,135,940 shares outstanding as of December 26, 2023, as reported in the company's Schedule 14A filed with the SEC. The filing was completed on February 14, 2024.
2023年12月31日，停战资本有限责任公司及其管理成员史蒂芬·博伊德向美国证券交易委员会提交了附表13G，披露了180生命科学公司9.99％的所有权。该文件显示，停战资本有限责任公司和史蒂芬·博伊德共持有该公司1,112,480股普通股。这些股票由停战资本主基金有限公司持有，Armistice Capital, LLC担任该公司的投资经理，赋予其对证券的投票权和投资权。该文件称，这些股份是在正常业务过程中收购的，不是为了改变或影响180生命科学公司的控制权。根据该公司向美国证券交易委员会提交的附表14A所述，所有权百分比基于截至2023年12月26日的11,135,940股已发行股票。该申请于 2024 年 2 月 14 日完成。
2023年12月31日，停战资本有限责任公司及其管理成员史蒂芬·博伊德向美国证券交易委员会提交了附表13G，披露了180生命科学公司9.99％的所有权。该文件显示，停战资本有限责任公司和史蒂芬·博伊德共持有该公司1,112,480股普通股。这些股票由停战资本主基金有限公司持有，Armistice Capital, LLC担任该公司的投资经理，赋予其对证券的投票权和投资权。该文件称，这些股份是在正常业务过程中收购的，不是为了改变或影响180生命科学公司的控制权。根据该公司向美国证券交易委员会提交的附表14A所述，所有权百分比基于截至2023年12月26日的11,135,940股已发行股票。该申请于 2024 年 2 月 14 日完成。
有用
没用
